Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer (Q34536176)

2 August 2017

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer (English)

1 reference

2 August 2017

0 references

0 references

13

Steven A Rosenberg

1 reference

2 August 2017

6

Patrick Hwu

1 reference

2 August 2017

4

Suzanne L Topalian

1 reference

2 August 2017

James C Yang

1

1 reference

2 August 2017

Richard M Sherry

2

1 reference

2 August 2017

Seth M Steinberg

3

1 reference

2 August 2017

Douglas J Schwartzentruber

5

1 reference

2 August 2017

Claudia A Seipp

7

1 reference

2 August 2017

Linda Rogers-Freezer

8

1 reference

2 August 2017

Kathleen E Morton

9

1 reference

2 August 2017

Donald E White

10

1 reference

2 August 2017

David J Liewehr

11

1 reference

2 August 2017

Maria J Merino

12

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Journal of Clinical Oncology

2 August 2017

1 reference

2 August 2017

21

1 reference

2 August 2017

3127-3132

1 reference

2 August 2017

16

1 reference

Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

The Heidelberg classification of renal cell tumours.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275327

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

27 October 2018

1 reference

12 December 2020

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study

1 reference

12 December 2020

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

12 December 2020

Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma

1 reference

12 December 2020

[Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma]

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

High-dose aldesleukin in renal cell carcinoma: long-term survival update

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2003.02.122

1 reference

2 August 2017

1 reference

2 August 2017

1 reference